Gout patients with normalized uric acid are still recommended to take febuxostat at the lowest dose maintenance. Febuxostat is a kind of uric acid-lowering drug mainly used in the long-term treatment of gout and hyperuricemia, which exerts its efficacy by inhibiting the production of uric acid, and it is generally not recommended to stop taking it abruptly after the control of uric acid is normalized, but should be gradually reduced to the lowest dosage and maintained. Suddenly stop taking febuxostat may cause blood uric acid concentration rebound rise or even trigger acute gout attack, if the patient due to personal constitution, condition changes and other reasons lead to the need to stop taking febuxostat or change the treatment program, should be under the guidance of a physician to gradually stop taking the drug. Febuxostat must be used under medical supervision. It is recommended that patients with increased uric acid go to the rheumatology and immunology departments of regular hospitals for detailed consultation, and do not stop taking the drug without authorization.